Jennie Lin1, Hilda Fernandez2, Michael G S Shashaty3, Dan Negoianu1, Jeffrey M Testani4, Jeffrey S Berns1, Chirag R Parikh5, F Perry Wilson6. 1. Renal Electrolyte and Hypertension Division, Department of Medicine and. 2. Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, New York; and. 3. Pulmonary, Allergy, and Critical Care Division, Department of Medicine and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; 4. Sections of Cardiology and. 5. Nephrology and Program of Applied Translational Research, Department of Medicine, Yale School of Medicine, Yale University, New Haven, Connecticut. 6. Nephrology and Program of Applied Translational Research, Department of Medicine, Yale School of Medicine, Yale University, New Haven, Connecticut francis.p.wilson@yale.edu.
Abstract
BACKGROUND AND OBJECTIVES: Use of small changes in serum creatinine to diagnose AKI allows for earlier detection but may increase diagnostic false-positive rates because of inherent laboratory and biologic variabilities of creatinine. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We examined serum creatinine measurement characteristics in a prospective observational clinical reference cohort of 2267 adult patients with AKI by Kidney Disease Improving Global Outcomes creatinine criteria and used these data to create a simulation cohort to model AKI false-positive rates. We simulated up to seven successive blood draws on an equal population of hypothetical patients with unchanging true serum creatinine values. Error terms generated from laboratory and biologic variabilities were added to each simulated patient's true serum creatinine value to obtain the simulated measured serum creatinine for each blood draw. We determined the proportion of patients who would be erroneously diagnosed with AKI by Kidney Disease Improving Global Outcomes creatinine criteria. RESULTS: Within the clinical cohort, 75.0% of patients received four serum creatinine draws within at least one 48-hour period during hospitalization. After four simulated creatinine measurements that accounted for laboratory variability calculated from assay characteristics and 4.4% of biologic variability determined from the clinical cohort and publicly available data, the overall false-positive rate for AKI diagnosis was 8.0% (interquartile range =7.9%-8.1%), whereas patients with true serum creatinine ≥1.5 mg/dl (representing 21% of the clinical cohort) had a false-positive AKI diagnosis rate of 30.5% (interquartile range =30.1%-30.9%) versus 2.0% (interquartile range =1.9%-2.1%) in patients with true serum creatinine values <1.5 mg/dl (P<0.001). CONCLUSIONS: Use of small serum creatinine changes to diagnose AKI is limited by high false-positive rates caused by inherent variability of serum creatinine at higher baseline values, potentially misclassifying patients with CKD in AKI studies.
BACKGROUND AND OBJECTIVES: Use of small changes in serum creatinine to diagnose AKI allows for earlier detection but may increase diagnostic false-positive rates because of inherent laboratory and biologic variabilities of creatinine. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We examined serum creatinine measurement characteristics in a prospective observational clinical reference cohort of 2267 adult patients with AKI by Kidney Disease Improving Global Outcomes creatinine criteria and used these data to create a simulation cohort to model AKI false-positive rates. We simulated up to seven successive blood draws on an equal population of hypothetical patients with unchanging true serum creatinine values. Error terms generated from laboratory and biologic variabilities were added to each simulated patient's true serum creatinine value to obtain the simulated measured serum creatinine for each blood draw. We determined the proportion of patients who would be erroneously diagnosed with AKI by Kidney Disease Improving Global Outcomes creatinine criteria. RESULTS: Within the clinical cohort, 75.0% of patients received four serum creatinine draws within at least one 48-hour period during hospitalization. After four simulated creatinine measurements that accounted for laboratory variability calculated from assay characteristics and 4.4% of biologic variability determined from the clinical cohort and publicly available data, the overall false-positive rate for AKI diagnosis was 8.0% (interquartile range =7.9%-8.1%), whereas patients with true serum creatinine ≥1.5 mg/dl (representing 21% of the clinical cohort) had a false-positive AKI diagnosis rate of 30.5% (interquartile range =30.1%-30.9%) versus 2.0% (interquartile range =1.9%-2.1%) in patients with true serum creatinine values <1.5 mg/dl (P<0.001). CONCLUSIONS: Use of small serum creatinine changes to diagnose AKI is limited by high false-positive rates caused by inherent variability of serum creatinine at higher baseline values, potentially misclassifying patients with CKD in AKI studies.
Authors: A Ahsan Ejaz; Bhagwan Dass; Vijaykumar Lingegowda; Michiko Shimada; Thomas M Beaver; Noel I Ejaz; Amer S Abouhamze; Richard J Johnson Journal: Int Urol Nephrol Date: 2012-05-31 Impact factor: 2.370
Authors: Paul M Palevsky; Kathleen D Liu; Patrick D Brophy; Lakhmir S Chawla; Chirag R Parikh; Charuhas V Thakar; Ashita J Tolwani; Sushrut S Waikar; Steven D Weisbord Journal: Am J Kidney Dis Date: 2013-03-15 Impact factor: 8.860
Authors: Sean M Bagshaw; Garth Mortis; Christopher J Doig; Tomas Godinez-Luna; Gordon H Fick; Kevin B Laupland Journal: Am J Kidney Dis Date: 2006-09 Impact factor: 8.860
Authors: G M Chertow; S H Soroko; E P Paganini; K C Cho; J Himmelfarb; T A Ikizler; R L Mehta Journal: Kidney Int Date: 2006-07-19 Impact factor: 10.612
Authors: James A Tumlin; Kevin W Finkel; Patrick T Murray; Joshua Samuels; George Cotsonis; Andrew D Shaw Journal: Am J Kidney Dis Date: 2005-07 Impact factor: 8.860
Authors: Elizabeth Selvin; Stephen P Juraschek; John Eckfeldt; Andrew S Levey; Lesley A Inker; Josef Coresh Journal: Am J Kidney Dis Date: 2013-01-20 Impact factor: 8.860
Authors: Chi-Yuan Hsu; Raymond K Hsu; Kathleen D Liu; Jingrong Yang; Amanda Anderson; Jing Chen; Vernon M Chinchilli; Harold I Feldman; Amit X Garg; Lee Hamm; Jonathan Himmelfarb; James S Kaufman; John W Kusek; Chirag R Parikh; Ana C Ricardo; Sylvia E Rosas; Georges Saab; Daohang Sha; Edward D Siew; James Sondheimer; Jonathan J Taliercio; Wei Yang; Alan S Go Journal: J Am Soc Nephrol Date: 2019-06-24 Impact factor: 10.121
Authors: Sushrut S Waikar; Casey M Rebholz; Zihe Zheng; Shelley Hurwitz; Chi-Yuan Hsu; Harold I Feldman; Dawei Xie; Kathleen D Liu; Theodore E Mifflin; John H Eckfeldt; Paul L Kimmel; Ramachandran S Vasan; Joseph V Bonventre; Lesley A Inker; Josef Coresh Journal: Am J Kidney Dis Date: 2018-07-18 Impact factor: 8.860
Authors: Bixiao Zhao; Qiongshi Lu; Yuwei Cheng; Justin M Belcher; Edward D Siew; David E Leaf; Simon C Body; Amanda A Fox; Sushrut S Waikar; Charles D Collard; Heather Thiessen-Philbrook; T Alp Ikizler; Lorraine B Ware; Charles L Edelstein; Amit X Garg; Murim Choi; Jennifer A Schaub; Hongyu Zhao; Richard P Lifton; Chirag R Parikh Journal: Am J Respir Crit Care Med Date: 2017-02-15 Impact factor: 21.405
Authors: Chirag R Parikh; Caroline Liu; Maria K Mor; Paul M Palevsky; James S Kaufman; Heather Thiessen Philbrook; Steven D Weisbord Journal: Am J Kidney Dis Date: 2019-09-20 Impact factor: 8.860
Authors: David G Warnock; T Clark Powell; Edward D Siew; John P Donnelly; Henry E Wang; Ravindra L Mehta Journal: Nephron Date: 2016-07-26 Impact factor: 2.847